Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 85

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 85
---
.Operating lease assets and lease liabilities as reported on the consolidated balance sheets are as follows (dollars in thousands):December 31,Balance Sheet Classification20242023AssetsOperating lease assetsOther assets$24,477 $28,994 Total lease assets$24,477 $28,994 LiabilitiesLease liabilities, currentOperating lease liabilities, current portionAccounts payable and accrued liabilities6,889 8,331 Lease liabilities, long-termOperating lease liabilities, long-termOperating lease liabilities, long-term27,382 33,196 Total lease liabilities$34,271 $41,527 The components of operating lease costs are as follows (dollars in thousands):Year Ended December 31,202420232022Operating lease cost:Fixed lease cost$8,945 $8,258 $8,239 Variable lease cost 5,475 5,998 4,608 Total $14,420 $14,256 $12,847 Supplemental cash flow information related to leases is as follows (dollars in thousands):Year Ended December 31,202420232022Cash paid for operating leases$17,283 $17,112 $12,883 Lease assets obtained for new operating leases3,662 7,170 1,867 

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Financial Statements (Continued)12. Leases (Continued)

The weighted average lease term and weighted average discount rate for operating leases are as follows:Year Ended December 31,20242023Weighted-average remaining lease term (years)7.07.3Weighted-average discount rate4.9 %4.5 %Future minimum lease payments under noncancellable operating leases as of December 31, 2024, are as follows (dollars in thousands):Operating LeasesYear ending December 31:2025 $8,234 20266,957 20274,735 20283,004 20293,064 Thereafter14,003 Total future minimum lease payments39,997 Less: Imputed interest (1)(5,726)Present value of lease liabilities$34,271 (1) Calculated using the interest rate for each lease.

13. Segment Reporting

The Company operates in one operating segment and therefore has only one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S.The Company